Could a PET scan let kidney cancer patients pause treatment?
NCT ID NCT07175480
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing whether PET/CT scans can safely guide treatment pauses in people with advanced kidney cancer. Participants who have responded well to at least 12 months of standard therapy (immunotherapy plus targeted drugs) will stop treatment and be monitored with PET scans. The goal is to see if this approach can maintain cancer control while giving patients a break from medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PD-1/PD-L1 immune checkpoint inhibitor and VEGFR-tyrosine kinase inhibitor (treatment pause strategy)
- What this could lead to
- If successful, this could offer a way for some patients with advanced kidney cancer to safely take breaks from treatment, reducing side effects and improving quality of life.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The treatment pause could lead to cancer progression in some patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA ( MRCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
RECRUITINGNanjing, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can fasting two days a week slow kidney cancer? a new trial tests the idea
- Cell therapy combo aims to boost kidney cancer treatment
- First-in-Class cancer drug targets Hard-to-Treat tumors
- Immunotherapy after kidney cancer surgery: can a blood test predict who stays Cancer-Free?
- Engineered immune cells take on kidney cancer in first human test
- No clamps, no stitches: new robotic surgery aims to save more kidney function